Grail, Inc. was incorporated in Delaware on September 11, 2015. The company is a healthcare company dedicated to saving lives and improving health by pioneering new technologies for early cancer detection. It has built a multidisciplinary organization of scientists, engineers, and physicians, leveraging the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer and data science to overcome one of medicine's greatest challenges. Using its platform technology, the company has developed a multi-cancer early detection blood test that has demonstrated in clinical studies the ability to detect over 50 cancer types from a single blood draw while accurately identifying the origin of the cancer signal with high precision.